Industry News
Pharmaceutical Industry News
As Recipharm continues to refine…
As Recipharm continues to refine its footprint, the CDMO is selling its development and small-scale active pharmaceutical ingredient (API) manufacturing facility in Yavne, Israel, to Scinai Immunotherapeutics.
In his report, Senator Bill…
In his report, Senator Bill Cassidy suggested a slate of changes to the FDA to support broader drug access and to reduce regulatory burdens on drugmakers.
Less than half a year after…
Less than half a year after winning an inaugural green light in chronic hives, Novartis’ oral BTK inhibitor Rhapsido is jockeying to expand its urticaria reach into a new indication where it has the potential
Six weeks after Eli…
Six weeks after Eli Lilly revealed the success of phase 3b trial testing a combination of Zepbound and Taltz in patients with psoriatic arthritis, the Indianapolis company has reported another trial victory with the combination treatment
Eli Lilly is partnering on Team…
Eli Lilly is partnering on Team USA’s push to help Olympic athletes hurdle the challenges of recovering from injury. And, with increased awareness of the program on the agenda, the drugmaker has enlisted former basketball
As it looks ahead to the potential…
As it looks ahead to the potential launch of its sustained-delivery treatment Duravyu for wet age-related macular degeneration and diabetic macular edema, EyePoint has tapped a new commercial leader with experience heading up ophthalmology franchises
Stada will invest more than 85…
Stada will invest more than 85 million euros (around $101 million) to build a new production facility in Saudi Arabia, which will ultimately serve as a supply hub for the broader Middle East and North
Bayer has spent years working to…
Bayer has spent years working to get a handle on its Roundup legal mess. With a multibillion-dollar deal unveiled Tuesday, it's moving a step closer to that goal.
Shaped primarily by discussions…
Shaped primarily by discussions with Gen Xers and older millennials, a new campaign from a coalition formed by the CDC Foundation is using a familiar aesthetic to educate adults about managing high blood pressure.
The company is confident that…
The company is confident that results from a head-to-head trial against Regeneron's Eylea could make Axpaxli "one of the most consequential advances in retina," CEO Pravin Dugel, M.D., said in a statement. Investors were unimpressed,
Six years after the FDA approved…
Six years after the FDA approved Eli Lilly’s Retevmo to treat lung and thyroid cancers with a rare biomarker, the Indianapolis drugmaker is laying groundwork to move the treatment into the adjuvant setting, reporting the
Continuing the reinvention of its…
Continuing the reinvention of its cancer drug Gazyva as a treatment for immune-mediated diseases of the kidney—which resulted in a lupus nephritis nod last fall—Roche is touting new data that could tee up the antibody
Serving on Sanofi’s executive…
Serving on Sanofi's executive committee, Buxo will form part of Belén Garijo's leadership team when the outgoing Merck KGaA chief joins Sanofi as CEO at the end of April.
The clamor for radioisotopes has…
The clamor for radioisotopes has continued into the new year, with Novartis inking a deal with radiopharmaceutical producer Niowave to supply the pharma giant with the specialized ingredient Actinium-225 (Ac-225) used to develop targeted cancer
Vaccine Makers Curtail Research and Cut Jobs
Federal policies under Robert F. Kennedy Jr. that are hostile to vaccines have “sent a chill through the entire industry,” one scientist said.
Should Drug Companies Be Advertising to Consumers?
Aging means “becoming a target” of the industry, one expert said. After decades of debate, politicians of all stripes are proposing bans.
Determined to avoid a repeat of…
Determined to avoid a repeat of the supply shortfalls that plagued early GLP-1 rollouts for obesity, Eli Lilly has amassed a sizable store of its oral weight loss candidate orforglipron. Specifically, Lilly had secured “pre-launch
Friday’s RFI sets a March 19…
Friday’s RFI sets a March 19 deadline for stakeholders to weigh in on what the government should consider when putting together its second attempt at a 340B rebate test run.
A new campaign for Astellas…
A new campaign for Astellas Pharma’s Izervay is aimed at opening retina specialists’ eyes to the unique role they play in their geographic atrophy patients’ lives.
Vertex expects $500 million in…
Vertex expects $500 million in 2026 from new products outside of its flagship cystic fibrosis franchise. In 2025, those drugs delivered a combined total of $175.6 million.